I agree, very positive. The fact that they are splitting trial cost is a help as well. Many of these PD-1 combo studies make the smaller the company pay.
They're also looking for CR and PFS at 6 mo for the end points, so hopefully we can get some interim data by year's end. I think one thing that has been holding this back, is no true efficacy data yet, just immune response. Will be great once we get some prelim results.
News 
Market Data 
Discover 
